dual therapy did not reduce cardiovascular or renal outcomes compared with either angiotensin-converting enzyme inhibitors or angiotensin receptor blockers alone. Previous controlled trials with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers have demonstrated greater cardiovascular and renal benefit in people with renal risk. We hypothesized that dual therapy would be more effective than monotherapy in patients with low glomerular filtration rate and elevated albuminuria. Methods and Results-Post hoc analysis was performed of renal subgroups of dual therapy versus monotherapy for the ONTARGET study and angiotensin receptor blocker versus placebo for the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (TRANSCEND). The studies featured hazard ratios by subgroups and Cox regression models with factors for treatment, subgroup, and interactions. The main cardiovascular outcome was the composite of cardiovascular death, myocardial infarction, stroke, or hospitalization for heart failure, and the main renal outcome was the composite of chronic dialysis or doubling of creatinine. In ONTARGET, there was no cardiovascular or renal benefit from dual over monotherapy in any subgroup, even with low glomerular filtration rate and/or elevated albuminuria. In TRANSCEND, in the comparison of angiotensin receptor blocker with placebo, there was a significant interaction for the main renal outcome (Pϭ0.01) in the direction of harm for patients with normoalbuminuria (0.37 versus 0.16 events per 100 patient-years; hazard ratio, 2.35; confidence interval, 1.33 to 4.15) but a trend to benefit with microalbuminuria (0.52 versus 0.89 events per 100 patient-years; hazard ratio, 0.60; confidence interval, 0.25 to 1.46) and macroalbuminuria (1.57 versus 2.60 events per 100 patient-years; hazard ratio, 0.71; confidence interval, 0.21 to 2.44). Conclusions-This post hoc analysis does not support dual therapy over monotherapy in high-vascular risk patients with low glomerular filtration rate or albuminuria. This observation is a post hoc comparison and should be interpreted appropriately. Clinical Trial Registration-URL: http://clinicaltrials
C hronic kidney disease is associated with accelerated cardiovascular disease. 1 For example, in post-myocardial infarction patients with estimated glomerular filtration rate (eGFR) Ͻ60 but Ͼ45 mL/min per 1.73 m 2 , total mortality was 25% higher 2 than with an eGFR Ͼ60 mL/min per 1.73 m 2 , and after an acute coronary artery syndrome, a fall in GFR also was associated with worse cardiovascular outcomes. 3 Blockade of the renin-angiotensin-aldosterone system (RAAS) is associated with less renal progression 4 and therefore potentially with better cardiovascular outcomes. Indeed, RAAS blockade with an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB) in patients with cardiovascular risk and a low eGFR significantly lowered the risk for cardiovascular mortality. 5, 6 More intense inhibition of the RAAS with an ACE inhibitor and an ARB ("dual therapy") reduced albuminuria to a greater extent than either drug alone, but major cardiovascular or renal end points were not examined. 7 The recent Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET) assessed major cardiovascular and renal end points; dual therapy was associated with less progression of albuminuria overall 8 but not with improvement of major cardiovascular and renal outcomes. 9 Furthermore, dual therapy was associated with increased adverse events including acute kidney injury and hyperkalemia compared with monotherapy with an ACE inhibitor or ARB alone. 8 In the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (TRANSCEND), an ARB improved the secondary Heart Outcomes Prevention Evaluation (HOPE) outcome but not the primary cardiovascular end point including congestive heart failure. 10, 11 It also lowered the risk of worsening albuminuria compared with placebo but was not associated with improved renal outcomes that would be of importance to patients. 10, 11 
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Some have speculated that dual blockade might result in better cardiovascular and renal outcomes, but only in those with known renal disease, particularly in those with low GFR or macroalbuminuria. [12] [13] [14] [15] The renal subanalysis of the HOPE study suggested that benefits from RAAS blockade may indeed be greater in those with chronic kidney disease. 5 To investigate whether dual RAAS blockade had greater beneficial effects in patients with known low GFR or albuminuria, we undertook a post hoc analysis of the ONTARGET and TRANSCEND data sets, examining major cardiovascular and renal outcomes in participants with renal risk markers. In the ONTARGET study, Ͼ5600 participants had low eGFR, Ͼ3800 had microalbuminuria, and Ͼ1200 had macroalbuminuria, numbers that are comparable to those from major renal trials. 8 It is of interest to know whether low renal function and/or albuminuria is associated with increased ability to benefit from dual blockade of the RAAS in patients at high cardiovascular risk. We also report the efficacy of ARB use compared with placebo in participants with renal risk markers in TRANSCEND.
Methods
As described in detail previously, 8, 10 we enrolled participants who were aged Ն55 years with established atherosclerotic vascular disease or with diabetes mellitus with end-organ damage. Exclusion criteria included a serum creatinine level Ͼ265 mol/L (3 mg/dL), significant renal artery stenosis, uncorrected volume or sodium depletion, and uncontrolled hypertension (Ͼ160 mm Hg systolic and/or Ͼ100 mm Hg diastolic), heart failure, unexplained syncope, planned cardiac surgery, and cardiac revascularization within the previous 3 months. In TRANSCEND, only people intolerant to ACE inhibitors were included. Macroalbuminuria was an exclusion criterion in TRANSCEND but was found in 135 participants when urine was analyzed centrally. 10, 11 After a 3-week run-in period, participants were randomized to telmisartan 80 mg/d, ramipril 10 mg/d, or their combination (ONTARGET) or to telmisartan 80 mg/d or placebo (TRANSCEND). Consenting participants were randomized between November 2001 and May 2004 and followed until August 2008. The study received approval from research ethics boards and was performed according to the principles of good clinical practice. Investigators, participants, and all trial collaborators were blinded to treatment allocation except for a trial-independent statistician and the members of the independent data safety and monitoring board. A total of 25 620 participants were randomized in ONTARGET and 5926 in TRANSCEND, and this analysis includes only participants with baseline serum creatinine and urinary albumin-to-creatinine ratio (ACR) (nϭ23 422 for ONTARGET and nϭ5398 for TRANSCEND). Except for minor differences in the proportion of women, of left ventricular hypertrophy, and of smoking, clinical characteristics were the same in all participants and in those included in the present analysis.
Participants were followed after 6 weeks and then every 6 months thereafter for a median of 56 months. Serum creatinine was measured before the run-in period, 6 weeks after randomization, after 2 years, and at study end. The urinary ACR was measured before the run-in period, at 2 years, and at the penultimate visit. 16 A value Ն2.0 mg/mmol to 20 mg/mmol for men and Ն2.8 mg/mmol to 28 mg/mmol for women was defined as microalbuminuria, and a value Ͼ20 mg/mmol or Ͼ28 mg/mmol for men and women, respectively, was defined as macroalbuminuria 17 (multiply by 8.84 for mg/g). Although the American Diabetes Association defines microalbuminuria as ACR values of 3.3 to 33 mg/mmol for both men and women (roughly equivalent to 30 to 300 mg/g creatinine and 30 to 300 mg/d of urinary albumin), sex-specific values were chosen to account for different muscle mass 18 and the cutoffs based on the work of Warram et al. 19 A more conservative definition was used in the main publication of both ONTARGET and TRANSCEND, namely, 3.4 to 33.9 mg/mmol and Ͼ33.9 mg/mmol, independent of gender, for microalbuminuria and macroalbuminuria, respectively. 8, 10 Urine tests were measured centrally as detailed before. 8, 10 Serum creatinine was measured locally at the study sites, and values Ͻ0.4 mg/dL were considered implausible and excluded from the analysis. 9 The eGFR was calculated with the use of the 4-variable Modification of Diet in Renal Disease formula. 20 An eGFR Ͻ60 mL/min per 1.73 m 2 was used as the cut point for low GFR. All primary outcomes were adjudicated by an independent committee. Information about dialysis was asked at each visit. After trial conclusion, a questionnaire was sent to sites having reported instances of dialysis, and information on the duration of dialysis and primary reason for dialysis was not obtained in only 3 of 162 instances. Acute dialysis was defined as a duration Յ2 months, and chronic dialysis was defined as a duration Ͼ2 months. This analysis includes 144 of these cases of dialysis (87 chronic and 57 acute).
Statistical Analysis
Continuous data are given as meanϮSD and categorical data as actual frequencies and percentages. The primary analysis used an intention-to-treat time-to-event approach. Treatment comparisons with regard to time-to-event-related data (based on Cox regression of time to occurrence of first event) are displayed as hazard ratios with 95% confidence intervals (CIs). Analyses of subgroups were performed with the use of the Cox regression model with factors for treatment, subgroup, and interactions. Treatment comparisons with regard to total discontinuations were performed with 2 testing by comparing the proportion of discontinuations. The Breslow-Day method was used to test the homogeneity among subgroups. All P values are 2 sided. Comparisons for categorical data use the 2 test with t tests for continuous variables. ACR values were not normally distributed and are therefore log-transformed before analysis and displayed as the geometric mean and 95% CIs. To increase the statistical power of the ONTARGET data set, the 2 monotherapy groups, ramipril and telmisartan, were combined into 1 monotherapy group. For the various subgroups analyzed here, randomization to the 3 treatment groups (telmisartan versus ramipril versus both) for ONTARGET or 2 treatment groups (telmisartan versus placebo) for TRANSCEND resulted in well-balanced baseline characteristics (data not shown). It is recognized that in any subgroup analysis there is a dramatic and disproportionate loss of power in subgroup analysis with the attendant reduction in sample size. 21 Therefore, because of the risk of multiple comparisons with 2 GFR conditions, 3 albuminuria conditions, 3 time points, and 2 treatment groups, further exploration for possible mechanistic effects of changes of blood pressure or albuminuria on outcomes was not performed. ONTARGET indicates Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial; GFR, glomerular filtration rate; CI, confidence interval; P1, effect of treatment difference according to estimated GFR; P2, effect of treatment difference according to albuminuria; and P3, effect of treatment difference according to both estimated GFR and albuminuria.
Results

Monotherapy Versus Dual Therapy (ONTARGET)
Baseline Data
The study population was subdivided into 6 groups on the basis of normal or low GFR and normoalbuminuria, microalbuminuria, or macroalbuminuria on the basis of the ACR. Overall, a low GFR (eGFR Ͻ60 mL/min per 1.73 m 2 ) was detected in 5623 (24.0%), microalbuminuria in 3809 (16.3%), and macroalbuminuria in 1287 (5.5%) ( Table 1) . Greater albuminuria levels at any level of GFR were associated with a greater prevalence of hypertension, diabetes mellitus, and left ventricular hypertrophy, a greater use of calcium channel blockers and diuretics, but also a lesser use of statins and aspirin. The finding of microalbuminuria or macroalbuminuria at baseline was associated with a fall in GFR over time in the low-GFR group but not in the normal-GFR group.
Cardiovascular Outcomes and Death
The rate of the primary cardiovascular outcome was much greater than that of the composite renal outcome. Compared with the normoalbuminuria group, the rate doubled and tripled in the microalbuminuria and macroalbuminuria groups, respectively ( Table 2) . No improvement in cardiovascular outcome was found with dual therapy over monotherapy even in the high-renal risk group with low GFR and macroalbuminuria ( Figure 1 and Table 2 ). An interaction was found for all-cause mortality between albuminuria and dual therapy, independent of GFR level; participants with normoalbuminuria had higher mortality with dual therapy than with monotherapy (10.29% versus 9.21%; hazard ratio, 1.13; 95% CI, 1.02 to 1.24; Pϭ0.018). Participants with macroalbuminuria, however, had a trend to lower mortality (25.06% versus 30.91%; hazard ratio, 0.8; 95% CI, 0.64 to 1.01; Pϭ0.056) ( Table 2) .
Renal Outcomes
The primary renal outcome, chronic dialysis or doubling of creatinine, occurred in 469 patients (Table 2) . Overall, dual therapy was associated with more primary renal outcomes (relative increase of 21%; 95% CI, 0% to 46%) compared with monotherapy, with no significant interaction with GFR or albuminuria. No subgroup showed a renal benefit with dual blockade, even those with low GFR and macroalbuminuria ( Figure 1 ). There was an unexpected trend for dual therapy to increase chronic dialysis or doubling of creatinine in the highest-risk group with low GFR and macroalbuminuria compared with monotherapy (63% risk increase; 95% CI, 5% to 151%). Doubling of serum creatinine occurred in 417 patients and chronic dialysis in 87 patients. There were trends towards a 69% increase in the risk of chronic dialysis and a 50% increase in risk of doubling creatinine in the highest-risk group with low GFR and macroalbuminuria.
Urinary albumin excretion increased from baseline despite RAAS blockade in patients with normoalbuminuria but fell in those with microalbuminuria or macroalbuminuria (Figure 1 ) but only for participants with a normal GFR. In the latter, the ACR fell more from baseline with dual therapy compared with monotherapy at 2 years (0.91 ratio of dual therapy/ monotherapy; 95% CI, 0.86 to 0.96; PϽ0.001) and at the final visit (0.94 ratio of dual therapy/monotherapy; 95% CI, 0.89 to 1.00; Pϭ0.035) (Figure 2 ). Blood pressure fell in all groups from baseline and remained lower overall throughout the study. (See Table I in the online-only Data Supplement for blood pressures by subgroup.) Table I in the online-only Data Supplement demonstrates a tendency for a greater fall in blood pressure from baseline with dual therapy compared with monotherapy in the normoalbuminuria subgroups but no such tendency in those with macroalbuminuria.
Adverse Events
Dual therapy led to more acute dialysis-dependent renal failure (0.08 versus 0.04 events per 100 patient-years; Pϭ0.02) and more hyperkalemia (1.29 versus 0.74 events per 100 patient-years; PϽ0.001) compared with monotherapy (Table 3) . There was no significant interaction between eGFR and albuminuria. Medication discontinuation in dual therapy compared with monotherapy groups overall was greatest in patients with normoalbuminuria (interaction Pϭ0.006) (Table II in the online-only Data Supplement). Discontinuation for hypotension was more frequent with dual therapy compared with monotherapy, with the difference being greatest with normal GFR (interaction Pϭ0.018). There were otherwise no statistically significant interactions for any of the other adverse reactions leading to discontinuation. Approxi- mately 0.7% of all participants (nϭ1644) reported taking nonsteroidal anti-inflammatory drugs at baseline (dose and duration not recorded). There was no evidence of an interaction between dual therapy or monotherapy and hyperkalemia or acute renal failure by nonsteroidal anti-inflammatory drug intake (data not shown).
Telmisartan Versus Placebo (TRANSCEND)
Baseline Data ACR and eGFR were available in 5398 participants, and 1480 had low GFR, 695 microalbuminuria, and 135 macroalbuminuria (despite its being a study exclusion criterion) ( Table  III in the online-only Data Supplement). Blood pressure was higher in participants with low compared with normal GFR. With greater albuminuria, baseline eGFR trended lower in the low-GFR group. Higher levels of albuminuria were associated with higher blood pressure, a greater prevalence of hypertension, diabetes mellitus, and left ventricular hypertrophy, and greater use of calcium channel blockers.
Cardiovascular Outcomes and Death
The rate of the primary cardiovascular outcome was greater than that of the composite renal outcome (Table IV in the online-only Data Supplement). No improvement in cardiovascular outcome or death was found with ARB therapy over placebo in participants with renal risk markers.
Renal Outcomes
The primary renal outcome, doubling of creatinine or chronic dialysis, occurred in 89 patients. Although overall, there was no evidence of renal benefit in those assigned to telmisartan for the combined renal outcome (relative increase of 38%; 95% CI, Ϫ10% to ϩ110%), interactions were found for both albuminuria and GFR. Patients with normoalbuminuria had an increase in renal outcomes (a 135% greater renal risk from telmisartan), and patients with microalbuminuria or macroalbuminuria had a trend towards a decrease of 40% and 29%, respectively, in renal outcomes with telmisartan compared with placebo. Patients with a normal GFR at baseline had a trend in the direction of harm (71% greater renal risk from telmisartan; 95% CI, ϩ4% to ϩ180%), but patients with a low GFR at baseline had a trend towards a reduction of renal risk (26% lower renal risk from telmisartan; 95% CI, Ϫ69% to ϩ72%). Chronic dialysis occurred in only 10 participants.
Because of small numbers, the subgroup with both low GFR and macroalbuminuria could not be tested separately.
Adverse Events
In all participants taken together, hyperkalemia Ͼ5.5 mmol/L (145 events) was more frequent with telmisartan (0.81 versus 0.38 events per 100 patient-years with placebo; PϽ0.0001), and no interactions were found with GFR or albuminuria (Tables V and VI in the online-only Data Supplement). Severe hyperkalemia (Ͼ6.5 mmol/L) was rare (3 cases, all with telmisartan). Acute renal failure was reported in only 6 instances with no trends. Total discontinuations of therapy were fewer with telmisartan than with placebo.
Discussion
We analyzed ONTARGET and TRANSCEND, examining the effect of treatment in renal subgroups defined by GFR and albuminuria. Overall, we did not detect major interactions for the main cardiovascular or renal outcomes between treatment, GFR, and albuminuria in both studies. In ONTARGET, there was no cardiovascular or renal benefit of dual therapy over monotherapy even in subgroups at high renal risk. Adverse effects were more common with dual therapy. In TRANSCEND, there was a tendency for renal benefit from telmisartan for the main renal outcome in patients with microalbuminuria or macroalbuminuria but for harm with normoalbuminuria.
This analysis differs from the previously published main analyses in several ways. 9 For the ONTARGET analysis, we collapsed the groups of patients treated with ramipril and telmisartan into a single monotherapy group to maximize power to compare monotherapy with dual therapy. We specified doubling of creatinine or chronic dialysis as the main renal outcome and defined acute dialysis as an adverse event. In addition, we adapted the definition of microalbuminuria to gender.
Our hypothesis that treatment with combination therapy would be superior to monotherapy in subgroups at high risk for renal outcomes was based on previous observations showing that patients whose albuminuria level falls in response to RAAS blockade have improved cardiovascular and renal outcomes. This was found in patients with diabetic nephropathy and macroalbuminuria 22 and also in hypertensive subjects with left ventricular hypertrophy and normoal- buminuria and microalbuminuria. 23 A meta-analysis of 1860 patients from 11 randomized trials found that inhibition of the RAAS with ACE inhibitors reduces both end-stage renal disease and doubling of creatinine by 30%, 24 but the effect was limited to patients with macroalbuminuria. 25 Thus, there was the expectation that therapy that lowered proteinuria would also be protective for renal and possibly cardiovascular disorders.
The lack of additive benefit on renal outcomes with dual therapy in ONTARGET participants even in patients with low GFR and macroalbuminuria was therefore surprising. This is also despite a lower blood pressure overall in the dual therapy group, by 2.4/1.4 mm Hg compared with ramipril alone and by 1.5/0.8 mm Hg compared with telmisartan alone. A meta-analysis of 49 randomized trials found that dual therapy with an ACE inhibitor and an ARB had additional albuminuria-lowering effects by Ϸ20% over either class of drug alone but did not report major cardiovascular or renal outcomes. 7 In that meta-analysis, not every trial exhibited a greater decrease in albuminuria with dual therapy. 7 The largest clinical trial in patients with kidney disease and albuminuria to test major renal outcomes in addition to albuminuria reduction from dual RAAS blockade over monotherapy was the Combination Treatment of Angiotensin-II Receptor Blocker and Angiotensin-Converting-Enzyme Inhibitor in Non-Diabetic Renal Disease (COOPERATE) study, which is now recognized as unreliable 26 and retracted. 27 Three other randomized trials comparing monotherapy with dual therapy have included a total of 192 patients, but only 7 had doubling of creatinine and 4 had end-stage renal disease. 28 -30 Although our findings are unexpected, the data are robust. From study initiation, renal outcomes in ONTARGET were specified as the most important secondary outcome, and there was a prespecified plan to combine the ramipril and telmisartan groups into a monotherapy group in the event of equivalence between ramipril and telmisartan. Results are consistent between the objective outcome of chronic dialysis and the accepted outcome of doubling of serum creatinine or chronic dialysis. Our a priori hypothesis was that in ONTARGET's highestrisk group, those with macroalbuminuria and low GFR, dual therapy would have a positive impact independent of blood pressure lowering. In this subgroup of 608 participants, blood pressure and albuminuria were not lowered more by dual therapy than monotherapy, and there was no positive impact on major renal outcomes. Thus, the hypothesis was not borne out. As recently reviewed, the adverse effects of dual therapy in the ONTARGET population outweighed the potential benefits. 31 Whether RAAS blockade independent of blood pressure lowering can prevent clinically important renal events in patients at high vascular but relatively modest renal risk (normal or microalbuminuria) is still unclear. The HOPE study, the largest placebo-controlled study of this issue, demonstrated a 24% reduction in the development of macroalbuminuria, but end-stage renal disease was infrequent, and an end-of-study creatinine was measured only in people with diabetes mellitus. [32] [33] [34] Previous trials of ARB against placebo in nondiabetic renal disease are limited to 2 randomized studies of 165 patients and are unable to examine clinically important outcomes. 35, 36 In patients with diabetic nephropathy, a meta-analysis of 3 trials of 3251 patients found a reduction in end-stage renal disease with ARBs compared with placebo by 22%. 37 TRANSCEND, with an exclusion criterion for macroalbuminuria, would have excluded most of these patients and found no benefit overall for an ARB to prevent doubling of creatinine or dialysis. However, a significant interaction was found such that patients with normoalbuminuria did not benefit and had more adverse renal outcomes, whereas patients with microalbuminuria or macroalbuminuria had a trend toward renal benefit. The adverse event rates in this analysis are consistent with those reported previously by the Candesartan in Heart FailureAssessment of Reduction of Mortality and Morbidity (CHARM) study. 38 The TRANSCEND subanalyses do not support preferential use of ARBs over other antihypertensive therapy to prevent renal outcomes in patients with normoalbuminuria with normal or low GFR.
Our work has several limitations. In the comparison of telmisartan with placebo, only 82 patients experienced doubling of serum creatinine, and 10 required chronic dialysis. The post hoc review of dialysis duration was also a limitation, but incident cases of dialysis were prospectively collected. In both studies, few patients with GFR Ͻ30 mL/min per 1.73 m 2 were recruited. Both ONTARGET and TRANSCEND included patients selected on the basis of vascular and not renal risk. It is possible that effects are different in patients with specific renal diseases but free of vascular disease or in trials setting targets for albuminuria or lower blood pressure targets. The renal diagnosis of patients with low GFR in our studies is unknown; given the clinical characteristics, microvascular or macrovascular renal diseases are likely. Patients with diabetes mellitus and low GFR may not have had diabetic nephropathy, as suggested by the slow rates of GFR loss, similar to HOPE participants who had diabetes mellitus, 33 consistent with epidemiological observations that many people with diabetes mellitus and low GFR do not have diabetic nephropathy. 39 It is therefore possible that the response to dual blockade in patients with true glomerular disease might be different. Given the large number of secondary analyses presented without adjustment for multiple comparisons, the results reported here should be considered hypothesis generating. Our data were gathered in people with well-controlled blood pressure, and we excluded people with heart failure. We recognize that some people with cardiovascular and renal problems have uncontrolled hypertension or heart failure and that our results do not generalize to this group. Regression to the mean and biased censoring also affect interpretation of the results in change in albuminuria, as always. Awareness of this effect will be important in planning studies of patients with low eGFR, in that observed progression will be diluted by the tendency of those selected for the study to regress upward toward the mean.
In summary, planned renal subgroup analyses for dual therapy compared with monotherapy RAAS blockade demonstrated that there was no benefit for cardiovascular or renal outcomes even in patients at the highest renal risk with low GFR and macroalbuminuria. In ONTARGET analyses in patients whose risk is predominantly vascular, in which most had a GFR Ͼ30 mL/min per 1.73 m 2 and proteinuria of Ͻ1 g/d, monotherapy with an ACE inhibitor or an ARB had equivalent effects on cardiovascular and renal outcomes, and dual therapy was associated with greater harm, predominantly from renal events. TRANSCEND results suggest that an ARB may prevent clinically important renal outcomes but only in patients with elevated albuminuria.
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